Sleep Apnea Implant Works Well for Overweight People: Study

 

Sleep apnea

A recent study has revealed a crucial breakthrough in the treatment of obstructive sleep apnea (OSA), a serious condition that affects millions around the world.

According to this study, an implant known as a hypoglossal nerve stimulator has been shown to be most effective in people who are overweight, but not severely obese, providing a valuable alternative for those who cannot tolerate or refuse to use standard continuous positive pressure treatment in airways (CPAP).

Published in the prestigious journal JAMA Otolaryngology-Head & Neck Surgery, the study examined 76 patients who received the implant, revealing a significant relationship between body mass index (BMI) and the effectiveness of the device.

Led by Dr. Eric Landsness, assistant professor of neurology and sleep medicine at St. Louis University School of Medicine, the study found that while the implant was a viable option for people with a BMI up to 32, its effectiveness decreased drastically in patients with a BMI higher than this threshold.

The hypoglossal nerve stimulator, approved by the U.S. Food and Drug Administration in 2014, has emerged as a promising alternative for those who struggle with CPAP, a machine that many find uncomfortable or claustrophobic.

Also Read: How can you tell if you suffer from noise sensitivity?

At a cost ranging from $50,000 to $100,000, the implant has been covered by Medicare and several insurance companies, offering an option for patients who cannot adapt to conventional treatment.

However, the study also highlighted that the effectiveness of the implant was affected by other factors, such as the patient's sleeping position. Those who slept on their backs experienced less favorable results compared to those who slept on their sides.

Sleep and Obesity

These findings have raised new questions about patient selection criteria and understanding of the underlying mechanisms behind OSA. Kristen Knutson, a sleep specialist and associate professor of neurology at Northwestern University Feinberg School of Medicine, said that while the implant offers a valuable option, it is crucial to better understand how obesity and sleep position affect its effectiveness.

OSA, characterized by repeated interruption of breathing during sleep, poses significant health risks, ranging from cardiovascular disease to metabolic and mental disorders. Although the standard treatment has been CPAP, many patients face difficulties adapting to this therapy, underscoring the need for effective alternatives.

The hypoglossal nerve stimulator offers renewed hope for those struggling with OSA. Surgically placed, the device works by stimulating the tongue to prevent airway obstructions during sleep.

Although the adaptation process may take time and effort, the potential benefits are significant, offering a better quality of life for those suffering from this debilitating condition.

Dr. Brandon Peters-Mathews, board-certified in neurology and sleep medicine, emphasized the importance of carefully selecting patients for this treatment, ensuring that those who are most likely to respond positively benefit the most.

As research continues to advance in this area, a greater understanding of the factors that influence implant effectiveness is expected, providing new insights and treatment options for patients with OSA worldwide.